Michael Glode, MD

Professional Titles

• Emeritus Professor

Recognitions

• Statesman Award, American Society of Clinical Oncology (2009)
  
• Fellow, American College of Physicians (2008)
  
• Fellow American Society of Clinical Oncology, ASCO (2011)

Research Interests

Publications

• A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM. Invest New Drugs. 2007 Apr;25(2):139-46. Epub 2006 Nov 1. PMID: 17077998 [PubMed - in process]
• A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glode LM. Cancer. 2006 Jul 15;107(2):266-74.
• Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM. BJU Int. 2006 Aug;98(2):335-40.
• The case for adjuvant therapy for prostate cancer. LM Glode J Urol. 2006 Dec;176(6 Pt 2):S30-3. Review.
• The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines. Arthur C, Flaig T, Su LJ, Denney R, Barnes F, Glode LM. Ultrasonics. 2006 Nov 27; [Epub ahead of print]
• Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Flaig TW, Su LJ, Harrison G, Agarwal R, Glode LM. Int J Cancer. 2007 Jan 17; [Epub ahead of print]
• Flaig TW, Su LJ, Harrison G, Agarwal R, Glodé LM. Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells. Int J Cancer. 2007 May 1;120(9):2028-33.
• Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes. J Urol. 2007 Apr;177(4):1229-37. Review.
• Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F, Glodé LM. Prostate cancer in a man with multiple previous cancers. Oncology (Williston Park). 2007 Apr;21(5):611-4.
• Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007 Jun 1;25(16):2218-24
• Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2007 Nov 15;67(22):11083-91
• Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3248-55
• Management of the side effects of androgen deprivation therapy in men with prostate cancer. Flaig TW, Glodé LM. Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. Review.
• Metabolic syndrome and prostate cancer. Glode LM. Cancer. 2008 May 15;112(10):2103-5. No abstract available.
• Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM; Southwest Oncology Group. J Clin Oncol. 2008 Mar 20;26(9):1532-6.
• Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. J Clin Oncol. 2010 Mar 1;28(7):1099-105. Epub 2010 Jan 25.
• A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Flaig TW, Glodé M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. Prostate. 2010 Feb 1. [Epub ahead of print]
• Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW. Clin Cancer Res. 2011 Jul 1;17(13):4558-67. Epub 2011 May 10.
• Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Clemons J, Glodé LM, Gao D, Flaig TW. Urol Oncol. 2011 Jul 25. [Epub ahead of print]
• A rare case of metastatic renal epithelioid angiomyolipoma. Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW. Oncology (Williston Park). 2011 Aug;25(9):832-8. No abstract available.
• Proliferative tumor doubling times of prostatic carcinoma. Werahera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T. Prostate Cancer. 2011;2011:301850. Epub 2011 Sep 21.
• Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21.
• Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Clemons J, Glodé LM, Gao D, Flaig TW. Urol Oncol. 2013 Feb;31(2):198-204. doi: 10.1016/j.urolonc.2010.12.004. Epub 2011 Jul 27.
• Compositions and Methods for Treating Bladder Cancer United States Patent Application 20120232010 Kind Code: A1
• Beer, T., Glode, M., Lance, R., Greengold, R., Haynes, H., Sims, R., ... & Corman, J. (2013, September). P10-1, an open-label, multicenter study of sipuleucel-T in men with metastatic castrate-resistant prostate cancer (rnCRPC) previously treated with sipuleucel-T: Analysis of immunological data. In EUROPEAN JOURNAL OF CANCER (Vol. 49, pp. S700-S700). THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND: ELSEVIER SCI LTD.
• Glode, L. Michael, and Elaine Lam. "Nonseminomatous germ cell tumor of testis and interrupted treatment." Oncology (Williston Park, NY) 27.8 (2013): 822-823.
• Beer, T. M., Schellhammer, P. F., Corman, J. M., Glodé, L. M., Hall, S. J., Whitmore, J. B., ... & Penson, D. F. (2013). Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology, 82(2), 410-415.
• Dorff, T. B., & Glode, L. M. (2013). Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer. Current opinion in urology, 23(4), 366-371.
• Lam, E. T., & Glodé, L. M. (2013). Neoadjuvant and Adjuvant Hormonal and Chemotherapy for Prostate Cancer. Hematology/oncology clinics of North America, 27(6), 1189-1204.
• Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH. Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts. Mol Imaging Biol. 2015 Jan 6. [Epub ahead of print] PubMed PMID: 25561013
• Bourlon MT, Glodé LM, Crawford ED. Base of the skull metastases in metastatic castration-resistant prostate cancer. Oncology (Williston Park). 2014 Dec;28(12):1115-6, 1124. PubMed PMID: 25510811
• Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014 Oct;13(10):2361-71. PubMed PMID: 25122071
• Wittmann D, Skolarus T, Glodé LM. Reconsidering the Trade-offs of Prostate Cancer Screening. N Engl J Med. 2020 Sep 24;383(13):1289-1290. PubMed PMID: 32966735
• Goren A, Wambier CG, McCoy J, Shapiro J, Vaño-Galván S, Herrera S, Glode LM. Clock genes may drive seasonal variation in SARS-CoV-2 infectivity: are we due for a second wave of COVID-19 in the fall?. J Biol Regul Homeost Agents. 2020 Jul-Aug,;34(4):1455-1457. PubMed PMID: 32700513
• Halpern AL, Torphy RJ, McCarter MD, Sciotto CG, Glode LM, Robinson WA. A familial germline mutation in KIT associated with achalasia, mastocytosis and gastrointestinal stromal tumors shows response to kinase inhibitors. Cancer Genet. 2019 Apr;233-234:1-6. PubMed PMID: 31109590

Professional Memberships

• American Society of Clinical Oncology, Member
• American Association for Cancer Research, Member
• American College of Physicians (ACP), Fellow

Practice Locations

• University of Colorado Hospital

Specialty Information

• Internal Medicine, Board Certification (1975)
• Medical Oncology, Board Certification (1977)
• Molecular Biology - University Helsinki Finland, Specialized Training (1986)

• Cancers - Bladder Cancer
• Cancers - Chemotherapy
• Cancers - Kidney Cancer
• Cancers - Prostate Cancer
• Cancers - Testicular Cancer
• Cancers
• Cancers - Cancer Medicine
• Cancers - Urologic Cancer